

Please be sure to complete the following:

Company name: QuLab Medical, Ltd. * **Website:** www.qulabmedical.com *

CEO name: Dr. Idan Tamir *

Highlight the relevant session below -

1. Longevity - How to Complete the Centenarian Decathlon?
2. Do we Know Enough About the Brain to Treat Neurological Disorders?
3. Are Cancer Therapeutics Fulfilling the Promise?
4. Can we Successfully Diagnose and Guide Patients' Optimal Cancer Treatment?
5. AI Tapestry: Optimizing the Interaction of AI and Biopharma
6. Facts and Myths on Ex-Liver Drug Delivery and New Horizons to Cure Rare Disorders
7. Who Owns Health Decisions? The Changing Dynamics of Patient-Physician Relationships in the Digital Health Revolution
8. Robots Dancing with Humans in the Healthcare Systems and Homes
9. Are Medical Devices Still Relevant in the Context of New Biology?
10. Let Food be Thy Medicine and Medicine be Thy Food
11. How do we make Academic Translation Medicine replicable and relevant?
12. **Bio Convergence: Everything That Rises Must Converge**
13. High Pace Innovation in Dermatology & Medical Aesthetics
14. Navigating Global Collaborations in Times of Uncertainty: Can we turn challenges into growth opportunities?
15. Ophthalmology, from R&D to Commercialization

- **Title of the Presentation:**

CMOS-based sensors for the continuous monitoring of key metabolites – a novel diagnostic paradigm

- **Executive Summary / Investment Rational**

QuLab Medical is developing a novel Continuous Multi-metabolite Monitoring (CMM) patch platform. Development efforts are focused on cost-effective and scalable sensor and patch manufacturing processes, established through partnerships with FAB development centers such as INL (Portugal) and IMEC (Belgium). QuLab Medical has also partnered with several manufacturers, including Tower SC (Israel), for large-scale manufacturing of its core sensor technology. QuLab Medical's therapeutic indications are in diabetes and several additional chronic and acute indications. We focus on monitoring continuous changes in the physiological levels of several key metabolites, including glucose, lactate and ketone bodies. By providing real-time and simultaneous monitoring of these key metabolites a personalized continuous metabolic profile can be generated, leading to improved healthcare and wellness-related decisions. Our First-Q™ CMM patch will enter First-in-Man trials in Israel later this year.

- **Core Technology**

QuLab Medical's core technology is based on our patented EC-FET platform which

employs FAB-manufactured CMOS-based sensors for continuously monitoring key metabolites utilizing a unique minimally-invasive disposable patch. This provides a cost-effective solution for disease prediction and prevention, ensued by improved disease monitoring and management.